Diplomat to distribute Puma Biotechnology’s new cancer drug

Diplomat to distribute Puma Biotechnology’s new cancer drug

July 21, 2017 Off By Dino Mustafić

Diplomat Pharmacy will distribute Puma Biotechnology’s new product, Nerlynx, a kinase inhibitor approved by the US Food and Drug Administration (FDA).

Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.